Amicus Therapeutics Announces Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Amicus Therapeutics (FOLD) Prices 16.98M Common Secondary Offering at $13.25/Share
June 12, 2015 6:17 AM EDTAmicus Therapeutics (NASDAQ: FOLD) announced the pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses... More
Amicus Therapeutics (FOLD) Announces $150M Common Stock Offering
June 10, 2015 4:02 PM EDTAmicus Therapeutics (NASDAQ: FOLD) announced it has commenced a $150 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the proposed offering. Cowen and Company, LLC is acting as... More
